Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
6 Results for "
PARP-1-IN-3
" in MedChemExpress (MCE) Product Catalog:
Products (6)
6 Results for "PARP-1-IN-3" in MCE Product Catalog:
PARP-1-IN-3, a benzamide derivative, is a potent PARP-1 inhibitor with IC50 values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. PARP-1-IN-3 induces apoptosis and arrest cell cycle at G2/M phase. PARP-1-IN-3 can be used in research of cancer .
Cat. No.: HY-168722
PROTAC PARP1 degrader-3 is a PARP1 PROTAC degrader with a DC50 of 58.14 nM. PROTAC PARP1 degrader-3 promotes the ubiquitination and degradation of PARP1 via the ubiquitin-proteasome system. PROTAC PARP1 degrader-3 acts synergistically with SN-38 (HY-13704) to inhibit colorectal cancer. PROTAC PARP1 degrader-3 can be used in studies related to colorectal cancer .
Cat. No.: HY-168723
Target:
Research Areas:
Piperidine-C-Pip-C2-Pip-C2-OH is a PROTAC Linker that can be used to synthesize the PROTAC PARP1 degrader-3 (HY-168722) for tumor research .
Cat. No.: HY-181928
CAS No.: 3123529-62-1
Target:
Research Areas:
PARP1/c-Met-IN-3 (Compound L19) is a selective c-Met and PARP1 inhibitor, with an IC50 of 5.4 nM against c-Met and an IC50 of 3.7 nM against PARP1. PARP1/c-Met-IN-3 inhibits PARP2 enzymatic activity with an IC50 of 4.52 nM, and shows no specificity for PARP1 and PARP2. PARP1/c-Met-IN-3 induces cell cycle arrest and apoptosis. PARP1/c-Met-IN-3 exhibits anti-tumor activity against triple-negative breast cancer .
Cat. No.: HY-189293
PARP1 degrader-3 is a selective PARP1 degrader derived from Olaparib (HY-10162) bearing a bicyclo[1.1.1]pentane (BCP) hydrophobic tag. PARP1 degrader-3 degrades PARP1 with a DC50 of 4.31 μM. PARP1 degrader-3 induces PARP1 degradation primarily through the ubiquitin-proteasome system, and the HSP70/HSP90-associated protein quality control pathway may be involved in this process. PARP1 degrader-3 can be used for colorectal cancer-related research .
Cat. No.: HY-187177
CAS No.: 3067348-77-7
Research Areas:
Pomalidomide-C2-NHCO-C7-NHBoc is an E3 ligase ligand-linker conjugate, in which the E3 ligase ligand is Thalidomide 4-fluoride (HY-41547). Pomalidomide-C2-NHCO-C7-NHBoc can be conjugated with PARP1 ligand-3 (HY-200661) to synthesize the PARP1 PROTAC degrader CPP-13 (HY-187176) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
